In gynecological cancers tumor infiltrating lymphocytes and upregulation of immune-related gene signatures have been associated with a better prognosis. Knowledge of tumor immunogenicity and associated gene signatures suggests that the tumor immune landscape is a key determinant to define patient prognosis and potentially to predict response to immune-checkpoint inhibitors. The aim of this review is to give an overview of immune gene signatures across gynecology histological cancer types, defining their prognostic and potential predictive role. In the current review we will present data on these gene signatures, on immunohistochemical features and their potential importance to select patients potentially eligible to trials with immune-checkpoint inhibitors.
Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors / G. Curigliano. - In: SEMINARS IN CANCER BIOLOGY. - ISSN 1044-579X. - 52:Pt 2(2018), pp. 253-258.
|Titolo:||Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors|
CURIGLIANO, GIUSEPPE (Primo) (Corresponding)
|Parole Chiave:||Benefit from immune-checkpoint inhibitors benefit; Genomic determinants; Gyneco-oncological cancer; Transcriptomics; Biomarkers, Tumor; Female; Genital Neoplasms, Female; Genomics; Humans; Immunotherapy; Lymphocytes, Tumor-Infiltrating; Medical Oncology; Cancer Research|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.semcancer.2018.05.004|
|Appare nelle tipologie:||01 - Articolo su periodico|